Role of deferiprone in chelation therapy for transfusional iron overload
Open Access
- 1 July 2003
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 102 (1) , 17-24
- https://doi.org/10.1182/blood-2002-06-1867
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Antihistone and Other Autoantibodies in β-Thalassemia major Patients Receiving Iron ChelatorsActa Haematologica, 2002
- Iron chelation therapyReviews in Clinical and Experimental Hematology, 2000
- Oral iron chelation therapy for thalassaemia: an uncertain scene. AnnotationBritish Journal of Haematology, 2000
- Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia RegisterThe Lancet, 2000
- DeferiproneDrugs, 1999
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.Journal of Clinical Pathology, 1994
- Differential toxicity of α‐keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitroEuropean Journal of Haematology, 1994
- L1 (1,2‐dimethyl‐3‐hydroxypyrid‐4‐one) for oral iron chelation in patients with beta‐thalassaemia majorBritish Journal of Haematology, 1990
- Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major.Journal of Clinical Pathology, 1990